ERBB2 and neoplasm: It has been shown that proliferation is the strongest parameter predicting clinical outcome in hormone receptor-positive, HER2-negative patients, while immune response and tumor invasion appear to be the main biological processes involved in triple-negative and HER2-positive breast cancer.